Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [615]

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrozole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA

Effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA )

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrazole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.

First effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA. )

Latest developments in prostate cancer

Prof Peter Mulders, Prof Axel S. Merseburger, Prof Pablo Maroto, Prof Peter...

Latest developments in prostate cancer ( Prof Peter Mulders, Prof Axel S. Merseburger, Prof Pablo Maroto, Prof Peter Iversen )

Investigational ER degrader safe, with early signs of antitumour activity...

Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA

Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer ( Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA )

ASCO GU 2015 news roundup

Peter Goodwin - ecancer correspondent, London, UK

ASCO GU 2015 news roundup ( Peter Goodwin - ecancer correspondent, London, UK )

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in...

Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma ( Dr Mark Beresford - Royal United Hospitals Bath, Bath, UK )

Expert commentary on emerging research in genitourinary cancer

Dr Chris Parker - The Royal Marsden Hospital, London, UK

Expert commentary on emerging research in genitourinary cancer ( Dr Chris Parker - The Royal Marsden Hospital, London, UK )

Combination of dalantercept plus axitinib versus placebo plus axitinib in...

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )

More from ecancer